Characteristics of asymptomatic COVID-19 infection and progression: A multicenter, retrospective study.
Adolescent
Adult
Aged
Aged, 80 and over
Asymptomatic Infections
/ epidemiology
Betacoronavirus
COVID-19
Child
China
/ epidemiology
Coronavirus Infections
/ epidemiology
Disease Progression
Female
Humans
Male
Middle Aged
Pandemics
Pneumonia, Viral
/ epidemiology
Retrospective Studies
Risk Factors
SARS-CoV-2
Virus Shedding
Young Adult
COVID-19
asymptomatic
early treatment
hypertension
Journal
Virulence
ISSN: 2150-5608
Titre abrégé: Virulence
Pays: United States
ID NLM: 101531386
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
pubmed:
30
7
2020
medline:
28
8
2020
entrez:
30
7
2020
Statut:
ppublish
Résumé
Novel coronavirus disease 2019 (COVID-19), caused by novel coronavirus SARS-CoV-2, has spread globally since the end of 2019. Asymptomatic carriers are of great concern as they can undermine the interventions to stop the pandemic. However, there is limited information about the characteristics and outcomes of the asymptomatic patients. Therefore, we conducted this retrospective study and retrieved data of 79 asymptomatic COVID-19 patients at admission from three designated hospitals in Wuhan, China. The asymptomatic patients could happen at any age, ranged from 9 to 96 years. These patients also had lower levels of alanine aminotransferase and C-reactive protein. Patchy shadowing was the most common manifestation in computed tomography scan. Some asymptomatic carriers developed mild or moderate symptoms during hospitalization. Age and comorbidities, especially hypertension, may be predictive factors for symptom development in the initially asymptomatic carriers at admission. Early detection and treatment for these presymptomatic patients before symptom onset can shorten the communicable period for the coronavirus and reduce the occurrence of severe cases.
Identifiants
pubmed: 32722990
doi: 10.1080/21505594.2020.1802194
pmc: PMC7550018
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1006-1014Références
JAMA. 2020 Apr 14;323(14):1339-1340
pubmed: 32108857
Clin Infect Dis. 2020 Nov 5;71(8):2018
pubmed: 32271372
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
J Med Virol. 2020 Nov;92(11):2286-2287
pubmed: 32347980
Intensive Care Med. 2020 Jun;46(6):1114-1116
pubmed: 32236644
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
Ann Transl Med. 2020 Sep;8(17):1084
pubmed: 33145303
Comput Biol Med. 2023 May;158:106794
pubmed: 37044045
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Cell Res. 2020 Jun;30(6):541-543
pubmed: 32346074
J Med Virol. 2020 Oct;92(10):1755-1756
pubmed: 32270882
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Med (Lausanne). 2021 Jan 13;7:563893
pubmed: 33521006
Clin Microbiol Infect. 2020 Jul;26(7):957-959
pubmed: 32234453
N Engl J Med. 2020 Mar 5;382(10):970-971
pubmed: 32003551
Circ Res. 2020 Jun 5;126(12):1671-1681
pubmed: 32302265
JAMA. 2020 Apr 21;323(15):1502-1503
pubmed: 32105304